<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01807624</url>
  </required_header>
  <id_info>
    <org_study_id>SR 2-06</org_study_id>
    <nct_id>NCT01807624</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of Kovacaine Nasal Spray (24 Hour Blood Collection)</brief_title>
  <official_title>The Pharmacokinetics Of Tetracaine, Para-Butylaminobenzoic Acid, And Oxymetazoline After Intranasal Administration Of The Highest Phase 3 Dose Of Kovacaine™ Mist To Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Renatus, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Triligent International</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rho, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Analytical Bio-Chemistry Laboratories, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Renatus, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the pharmacokinetics/pharmacodynamics and safety of
      a nasal spray containing the anesthetic drug tetracaine in combination with oxymetazoline
      with blood draws over 24 hours.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine the pharmacokinetics and safety of tetracaine,
      para- butylaminobenzoic acid (PBBA), and oxymetazoline after intranasal administration of the
      highest Phase 3 dose of Kovacaine Mist (Tetracaine Hydrochloride with Oxymetazoline
      Hydrochloride) to healthy volunteers.

      This is an open-label, single-treatment, single-dose study in healthy volunteers in which all
      subjects will receive the highest Phase 3 dose of Kovacaine Mist on one occasion. No
      randomization is necessary for this single treatment, single dose study. A single study
      center will participate.

      Each subject will receive a single dose of Kovacaine Mist (3% tetracaine HCl with 0.05%
      oxymetazoline HCl) consisting of 3 sprays (each 0.2 mL) in one nostril not taking longer than
      8 minutes, for a total 0.6 mL dose containing 18 mg tetracaine HCl and 0.3 mg oxymetazoline
      HCl.

      The total dosing period will be 8 minutes. Subjects will be required to fast 10 hours prior
      to dosing and for four (4) hours after dosing. Water will be allowed ad lib during the study
      except for one (1) hour prior through one (1) hour after dose administration. Subjects will
      be admitted to the study unit no later than 2100 hours of the evening prior to drug
      administration and will remain in the unit until the 24 hour blood sample is collected and
      discharge procedures are completed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of Oxymetazoline and PBBA</measure>
    <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of Oxymetazoline and PBBA</measure>
    <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life of Oxymetazoline and PBBA</measure>
    <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t of Oxymetazoline and PBBA</measure>
    <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-infinity of Oxymetazoline and PBBA</measure>
    <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Increase in SBP &gt; 20 mmHg on 2 Consecutive Measurements After Administration of Study Medication</measure>
    <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in SBP &gt; 20 mmHg on 2 Consecutive Measurements After Administration of Study Medication</measure>
    <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in DBP &gt; 20 mmHg on 2 Consecutive Measurements After Administration of Study Medication</measure>
    <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in DBP &gt; 20 mmHg on 2 Consecutive Measurements After Administration of Study Medication</measure>
    <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in Pulse Rate &gt; 20 Bpm on 2 Consecutive Measurements After Administration of Study Medication</measure>
    <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in Pulse Rate &gt; 20 Bpm on 2 Consecutive Measurements After Administration of Study Medication</measure>
    <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SpO2 Increase of &gt; 5% on 2 Consecutive Measurements After Administration of Study Medication</measure>
    <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SpO2 Decrease of &gt; 5% on 2 Consecutive Measurements After Administration of Study Medication</measure>
    <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Kovacaine Mist</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 3 sprays will be administered at the start of the procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tetracaine HCl 3% and Oxymetazoline HCl 0.05%</intervention_name>
    <description>1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl (para-butylaminobenzoic acid or PABA is active metabolite)</description>
    <arm_group_label>Kovacaine Mist</arm_group_label>
    <other_name>Kovacaine Nasal Spray</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or non-pregnant, non-breast-feeding female subjects between the ages of 18 and 75
             years (inclusive).

          -  Can understand and sign the informed consent document, can communicate with the
             investigator, and can understand and comply with the requirements of the protocol.

          -  Body mass index between 18 and 35 BMI.

          -  Sufficiently healthy as determined by the investigator to receive the test medications
             and undergo the scheduled study procedure.

          -  Can breathe through both nostrils.

          -  Screening BP ≤ 140/90 mm Hg.

        Exclusion Criteria:

          -  History of clinically significant respiratory, gastrointestinal, renal, hepatic,
             neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or
             cardiovascular disease, including cardiac arrhythmia, narrow angle glaucoma and benign
             prostatic hypertrophy (in men), uncontrolled thyroid disease (including Hashimoto's
             Thyroiditis and lymphocytic thyroiditis), uncontrolled diabetes mellitus or any other
             condition which, in the opinion of the Principal Investigator, would jeopardize the
             safety of the subject or impact the validity of the study results.

          -  Has clinically significant abnormal findings on the physical examination, medical
             history, electrocardiogram (ECG), or clinical laboratory evaluation during screening.
             This includes current upper respiratory infections.

          -  Currently experiencing seasonal or perennial allergic rhinitis, recurrent nose-bleeds
             or asthma, or has a significant history of these conditions, in the opinion of the
             Investigator.

          -  Current, including the last 30 days, sinusitis or other upper respiratory infections.

          -  Nasal polyps, significant nasal or sinus surgery or other abnormality that may
             interfere with the dose administration.

          -  History of allergic or adverse responses to tetracaine, other ester local anesthetics,
             PBBA, oxymetazoline and its preservatives, or para-aminobenzoic acid as found in PABA
             containing sunscreens or any comparable or similar product.

          -  Donation of blood or plasma within 30 days of the first dose of Study Drug.

          -  Participation in a clinical trial within 30 days prior to the first dose of Study
             Drug.

          -  Use of any new over-the-counter (OTC) medication, including topical anesthetic creams
             or gels, vitamins, within seven days prior to the first dose of the Study Drug or
             during the study unless approved by the Principal Investigator.

          -  Any prescription medication, whose dose is not stable at the time of screening, as
             determined by the Principal Investigator.

          -  Treatment with any known enzyme altering drugs such as barbiturates, phenothiazines,
             cimetidine, carbamazepine, etc., within 30 days prior to the first dose of Study Drug
             or during the study.

          -  Smoking or use of tobacco products within 6 months prior to the first dose of Study
             Drug or during the study.

          -  Female trying to conceive, is pregnant, suspected of being pregnant, or is lactating.
             (Females of child-bearing potential will be required to take a serum pregnancy test at
             screening (up to 21 days prior to the start of the study, including the day of the
             study), as well as a urine pregnancy test at check-in to rule out pregnancy.)

          -  Positive serum pregnancy test at screening or urine pregnancy test at check-in for all
             women of childbearing potential.

          -  Positive blood screen for HIV, Hepatitis B surface antigen (HbSAg), or Hepatitis C, or
             a positive urine screen for alcohol, drugs of abuse, or cotinine.

          -  Have a history of pseudocholinesterase deficiency or previous prolonged paralysis with
             succinylcholine or difficulty waking up from general anesthesia.

          -  Have a history of alcoholism and/or drug abuse.

          -  Have taken a monoamine oxidase inhibitor or vasopressor drug within the past 3 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jim Mulvahill</last_name>
    <role>Study Chair</role>
    <affiliation>St. Renatus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jean Brown Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2013</study_first_submitted>
  <study_first_submitted_qc>March 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2013</study_first_posted>
  <results_first_submitted>November 2, 2016</results_first_submitted>
  <results_first_submitted_qc>November 2, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 29, 2016</results_first_posted>
  <disposition_first_submitted>May 15, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>May 15, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 8, 2015</disposition_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetic</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tetracaine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Phenylephrine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Kovacaine Nasal Spray</title>
          <description>Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 3 sprays will be administered at the start of the procedure
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%: 1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Kovacaine Nasal Spray</title>
          <description>Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 3 sprays will be administered at the start of the procedure
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%: 1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.7" spread="9.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Oxymetazoline and PBBA</title>
        <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Nasal Spray</title>
            <description>Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 3 sprays will be administered at the start of the procedure
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%: 1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Oxymetazoline and PBBA</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oxymetazoline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.79" spread="0.586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PBBA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="465" spread="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of Oxymetazoline and PBBA</title>
        <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Nasal Spray</title>
            <description>Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 3 sprays will be administered at the start of the procedure
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%: 1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of Oxymetazoline and PBBA</title>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oxymetazoline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PBBA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Half-life of Oxymetazoline and PBBA</title>
        <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Nasal Spray</title>
            <description>Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 3 sprays will be administered at the start of the procedure
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%: 1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl</description>
          </group>
        </group_list>
        <measure>
          <title>Half-life of Oxymetazoline and PBBA</title>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oxymetazoline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.23" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PBBA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t of Oxymetazoline and PBBA</title>
        <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Nasal Spray</title>
            <description>Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 3 sprays will be administered at the start of the procedure
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%: 1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t of Oxymetazoline and PBBA</title>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oxymetazoline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.67" spread="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PBBA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="960" spread="509"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-infinity of Oxymetazoline and PBBA</title>
        <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Nasal Spray</title>
            <description>Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 3 sprays will be administered at the start of the procedure
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%: 1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-infinity of Oxymetazoline and PBBA</title>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oxymetazoline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.24" spread="2.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PBBA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="973" spread="513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Increase in SBP &gt; 20 mmHg on 2 Consecutive Measurements After Administration of Study Medication</title>
        <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Nasal Spray</title>
            <description>Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 3 sprays will be administered at the start of the procedure
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%: 1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl</description>
          </group>
        </group_list>
        <measure>
          <title>Increase in SBP &gt; 20 mmHg on 2 Consecutive Measurements After Administration of Study Medication</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Decrease in SBP &gt; 20 mmHg on 2 Consecutive Measurements After Administration of Study Medication</title>
        <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Nasal Spray</title>
            <description>Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 3 sprays will be administered at the start of the procedure
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%: 1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl</description>
          </group>
        </group_list>
        <measure>
          <title>Decrease in SBP &gt; 20 mmHg on 2 Consecutive Measurements After Administration of Study Medication</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Increase in DBP &gt; 20 mmHg on 2 Consecutive Measurements After Administration of Study Medication</title>
        <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Nasal Spray</title>
            <description>Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 3 sprays will be administered at the start of the procedure
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%: 1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl</description>
          </group>
        </group_list>
        <measure>
          <title>Increase in DBP &gt; 20 mmHg on 2 Consecutive Measurements After Administration of Study Medication</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Decrease in DBP &gt; 20 mmHg on 2 Consecutive Measurements After Administration of Study Medication</title>
        <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Nasal Spray</title>
            <description>Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 3 sprays will be administered at the start of the procedure
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%: 1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl</description>
          </group>
        </group_list>
        <measure>
          <title>Decrease in DBP &gt; 20 mmHg on 2 Consecutive Measurements After Administration of Study Medication</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Increase in Pulse Rate &gt; 20 Bpm on 2 Consecutive Measurements After Administration of Study Medication</title>
        <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Nasal Spray</title>
            <description>Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 3 sprays will be administered at the start of the procedure
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%: 1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl</description>
          </group>
        </group_list>
        <measure>
          <title>Increase in Pulse Rate &gt; 20 Bpm on 2 Consecutive Measurements After Administration of Study Medication</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Decrease in Pulse Rate &gt; 20 Bpm on 2 Consecutive Measurements After Administration of Study Medication</title>
        <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Nasal Spray</title>
            <description>Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 3 sprays will be administered at the start of the procedure
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%: 1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl</description>
          </group>
        </group_list>
        <measure>
          <title>Decrease in Pulse Rate &gt; 20 Bpm on 2 Consecutive Measurements After Administration of Study Medication</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SpO2 Increase of &gt; 5% on 2 Consecutive Measurements After Administration of Study Medication</title>
        <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Nasal Spray</title>
            <description>Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 3 sprays will be administered at the start of the procedure
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%: 1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl</description>
          </group>
        </group_list>
        <measure>
          <title>SpO2 Increase of &gt; 5% on 2 Consecutive Measurements After Administration of Study Medication</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SpO2 Decrease of &gt; 5% on 2 Consecutive Measurements After Administration of Study Medication</title>
        <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Nasal Spray</title>
            <description>Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 3 sprays will be administered at the start of the procedure
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%: 1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl</description>
          </group>
        </group_list>
        <measure>
          <title>SpO2 Decrease of &gt; 5% on 2 Consecutive Measurements After Administration of Study Medication</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Kovacaine Nasal Spray</title>
          <description>Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 3 sprays will be administered at the start of the procedure
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%: 1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nasal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <description>Runny nose</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pharyngeal Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Derek Muse</name_or_title>
      <organization>Jean Brown Research Center</organization>
      <phone>(801) 261-2000</phone>
      <email>participate@jeanbrownresearch.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

